U.S., May 15 -- ClinicalTrials.gov registry received information related to the study (NCT06970132) titled 'Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation' on April 27.
Brief Summary: This Phase Ib/II, open-label, single-arm study evaluates the safety, tolerability, pharmacokinetics, and preliminary efficacy of SY-5933 tablets combined with CT-707 tablets in patients with advanced solid tumors harboring the KRAS p.G12C mutation. The Phase Ib includes a dose-escalation phase to determine the optimal dosing regimen based on safety and pharmacokinetic data. In Phase II, four cohorts will be enrolled: advanced KRAS p.G12C mutated non-small cell lung cancer (NSCLC), colorectal cancer, pancreatic cancer, and othe...